| MeSH term | MeSH ID | Detail |
|---|---|---|
| Prosthesis-Related Infections | D016459 | 7 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Tooth Discoloration | D014075 | 7 associated lipids |
| Sinusitis | D012852 | 9 associated lipids |
| Fusobacterium Infections | D005674 | 3 associated lipids |
| Enterocolitis, Pseudomembranous | D004761 | 8 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Pseudomonas Infections | D011552 | 25 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Owen RJ | Helicobacter pylori resists arrest. | 1999 | Gut | pmid:10075942 |
| Marais A et al. | Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. | 1999 | Gut | pmid:10075951 |
| de Jong JJ et al. | Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient. | 1999 | Transpl. Int. | pmid:10080410 |
| Ramirez J et al. | Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. | 1999 | Clin Ther | pmid:10090428 |
| Talley NJ et al. | Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. | 1999 | BMJ | pmid:10092259 |
| Khoo KH et al. | Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex. | 1999 | J. Biol. Chem. | pmid:10092667 |
| Torgano G et al. | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. | 1999 | Circulation | pmid:10096930 |
| Navuluri R and Yue S | Understanding peptic ulcer disease pharmacotherapeutics. | 1999 | Nurse Pract | pmid:10100245 |
| Fournier S et al. | Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192709 |
| Gómez-Gil E et al. | Clarithromycin-induced acute psychoses in peptic ulcer disease. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192720 |
| Lee CK et al. | Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. | 1999 | Vaccine | pmid:10195786 |
| Goto T et al. | [Erosive duodenitis after eradication therapy for Helicobacter pylori]. | 1999 | Nihon Shokakibyo Gakkai Zasshi | pmid:10047687 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Gilljam M et al. | Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. | 1999 | Eur. Respir. J. | pmid:10515412 |
| Rovira E et al. | Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. | 1999 | Respiration | pmid:10516537 |
| Huchon G | How to manage the low-risk patient with lower respiratory tract infection? | 1999 | Respiration | pmid:10577170 |
| Foster SF et al. | Chronic pneumonia caused by Mycobacterium thermoresistibile in a cat. | 1999 | J Small Anim Pract | pmid:10516950 |
| de Luis DA et al. | Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. | 1999 | Clin Nutr | pmid:10578022 |
| Goldberg EI et al. | Henoch-Schönlein purpura induced by clarithromycin. | 1999 | Int. J. Dermatol. | pmid:10517691 |
| Tanigawara Y et al. | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. | 1999 | Clin. Pharmacol. Ther. | pmid:10579481 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
| Gibson JR et al. | Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. | 1999 | J. Clin. Microbiol. | pmid:10523591 |
| Komatsu H et al. | Mycobacterium avium infection of the skin associated with lichen scrofulosorum: report of three cases. | 1999 | Br. J. Dermatol. | pmid:10583068 |
| Osato MS et al. | Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. | 1999 | Int. J. Antimicrob. Agents | pmid:10493611 |
| Hirsh DC and Jang SS | Antimicrobial susceptibility of Nocardia nova isolated from five cats with nocardiosis. | 1999 | J. Am. Vet. Med. Assoc. | pmid:10496134 |
| Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
| Ellenrieder V et al. | Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. | 1999 | Scand. J. Gastroenterol. | pmid:10499474 |
| Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
| Gomollón F et al. | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. | 1999 | Helicobacter | pmid:10597390 |
| Landesman KA et al. | Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. | 1999 | Conn Med | pmid:10500341 |
| Auclair B et al. | Potential interaction between itraconazole and clarithromycin. | 1999 | Pharmacotherapy | pmid:10600094 |
| Feldman M et al. | Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. | 1999 | Am. J. Physiol. | pmid:10600812 |
| Kamada T et al. | Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. | 1999 | Helicobacter | pmid:10469195 |
| Valencia IC et al. | Disseminated cutaneous Mycobacterium chelonae infection after injection of bovine embryonic cells. | 1999 | Int. J. Dermatol. | pmid:10561050 |
| Szlachcic A et al. | Helicobacter pylori and its eradication in rosacea. | 1999 | J. Physiol. Pharmacol. | pmid:10695558 |
| Lind T et al. | The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. | 1999 | Gastroenterology | pmid:9922303 |
| MartÃn de Argila C and Boixeda D | [A ration proposal for the eradicating treatment of Helicobacter pylori infection]. | 1999 | Med Clin (Barc) | pmid:10562929 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Kuipers EJ and Klinkenberg-Knol EC | Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. | 1999 | Gastroenterology | pmid:9922329 |
| Tanaka E et al. | Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:10471610 |
| Adeyemi EO et al. | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. | 1999 | Eur J Gastroenterol Hepatol | pmid:10563537 |
| Klapper SR and Patrinely JR | Periocular atypical mycobacterial infections. | 1999 | Ophthalmology | pmid:10485521 |
| Matsuoka M et al. | Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. | 1999 | Gut | pmid:10486356 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| Tyagi AK et al. | An unreported side effect of topical clarithromycin when used successfully to treat Mycobacterium avium-intracellulare keratitis. | 1999 | Cornea | pmid:10487437 |
| Lugannani C and Strickland C | Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients? | 1999 | J Fam Pract | pmid:10628582 |
| RodrÃguez Téllez M et al. | Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. | 1999 | Rev Esp Enferm Dig | pmid:10491487 |
| Gutiérrez-Cabano CA and Raynald AC | Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats. | 1999 | Dig. Dis. Sci. | pmid:10492159 |
| Blondon H | [Eradication of Helicobacter pylori: what is the effect on symptoms of non-ulcerous dyspepsia?]. | 1999 | Presse Med | pmid:10629694 |
| Uygun A et al. | Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. | 1999 | Clin Ther | pmid:10509849 |
| Cammarota G et al. | Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. | 1999 | Dig. Dis. Sci. | pmid:10630486 |
| Bortolotti M et al. | Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1999 | Dig. Dis. Sci. | pmid:10630494 |
| Furuta T et al. | Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. | 1999 | Clin. Pharmacol. Ther. | pmid:10511062 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Fattorini L et al. | Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice. | 1999 | Microb. Drug Resist. | pmid:10566874 |
| Talley NJ et al. | Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. | 1999 | N. Engl. J. Med. | pmid:10511608 |
| Lamouliatte H et al. | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10571611 |
| Baylor P and Williams K | Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. | 1999 | Clin. Infect. Dis. | pmid:10525003 |
| Stengel W | [Sporotrichoid mycobacteriosis caused by Mycobacterium marinum]. | 1999 | Dtsch. Med. Wochenschr. | pmid:10572519 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Enroth H et al. | Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. | 1999 | Clin. Infect. Dis. | pmid:10451171 |
| Anzueto A et al. | The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. | 1999 | Clin. Infect. Dis. | pmid:10451195 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Hoellman DB et al. | Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. | 1999 | J. Antimicrob. Chemother. | pmid:10382885 |
| Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
| Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
| Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
| Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
| Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
| Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
| Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
| Tomiyama Y et al. | [The combination therapy of clarithromycin and sparfloxacin for pulmonary Mycobacterium gordonae infection]. | 1999 | Kekkaku | pmid:10386036 |
| Katsura Y et al. | Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. | 1999 | J. Med. Chem. | pmid:10425101 |
| Marini RP et al. | Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. | 1999 | Am. J. Vet. Res. | pmid:10791942 |
| Grimm KJ | Treatment of Helicobacter pylori infection in functional dyspepsia. | 1999 | J Fam Pract | pmid:10428242 |
| McConnell SA and Amsden GW | Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. | 1999 | Pharmacotherapy | pmid:10212011 |
| Dubois J and St-Pierre C | In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10212753 |
| Abbott GW et al. | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | 1999 | Cell | pmid:10219239 |
| van der Hulst RW et al. | [Treatment of Helicobacter pylori infections]. | 1999 | Ned Tijdschr Geneeskd | pmid:10221109 |
| Stewart AK et al. | Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. | 1999 | Blood | pmid:10391696 |
| Tsukamoto T et al. | Biofilm in complicated urinary tract infection. | 1999 | Int. J. Antimicrob. Agents | pmid:10394976 |
| Alvarez-Elcoro S and Enzler MJ | The macrolides: erythromycin, clarithromycin, and azithromycin. | 1999 | Mayo Clin. Proc. | pmid:10377939 |
| Hafner R et al. | Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. | 1999 | J. Infect. Dis. | pmid:10395860 |
| Inoue M et al. | [Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs]. | 1999 | Jpn J Antibiot | pmid:10396687 |
| Son SW et al. | The response of rosacea to eradication of Helicobacter pylori. | 1999 | Br. J. Dermatol. | pmid:10354058 |
| Pilotto A et al. | Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10355512 |
| Jacoby EB and Porter KB | Helicobacter pylori infection and persistent hyperemesis gravidarum. | 1999 | Am J Perinatol | pmid:10355915 |
| Fost DA et al. | Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. | 1999 | J. Allergy Clin. Immunol. | pmid:10359882 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Lindeboom JA et al. | Clarithromycin as a single-modality treatment in mycobacterial avium-intracellular infections. | 1999 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:9927080 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| Carbon C and Poole MD | The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. | 1999 | J Chemother | pmid:10326741 |
| Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
| Khan AA et al. | Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. | 1999 | Int. J. Antimicrob. Agents | pmid:10221415 |
| Horgan SE et al. | Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection. | 1999 | J. Med. Microbiol. | pmid:10403423 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |